Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients

Johnny M. Hoang(University of Houston), Meghana V. Trivedi(University of Houston), Tito R. Mendoza(The University of Texas MD Anderson Cancer Center), Hua Chen(University of Houston), Dozie Dike(University of Houston), Michael L. Johnson(University of Houston), Jae-Kyu Lee(University of Houston), Navneet Upadhyay(Eli Lilly (United States)), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center)

Supportive Care in Cancer

July 23, 2019

10.1007/s00520-019-05004-8

Cited by 2

Related Papers

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

|JNCI Journal of the National Cancer Institute|2014|1.1k

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

|JAMA Oncology|2015|1k

Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II

|Value in Health|2009|309

Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer

|Clinical Cancer Research|2013|273

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

|Cancer Research|2018|221